Faropenem medoxomil: A treatment option in acute bacterial rhinosinusitis

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 6, 2006, Pages 923-937

  Hadley, James A ^a   Tillotson, Glenn S ^b   Tosiello, Robert ^b   Echols, Roger M ^b  

^a University Otolaryngology Associates   (United States)

^b Replidyne Inc   (United States)

Author keywords

Acute bacterial; Bacteriology; Cefuroxime axetil; Faropenem medoxomil; Rhinosinusitis; Sinusitis

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFDINIR; CEFOTIAM; CEFPODOXIME PROXETIL; CEFUROXIME AXETIL; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; FAROPENEM MEDOXOMIL; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; PENEM DERIVATIVE; PENICILLIN G; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPIRATION BIOPSY; BACTERIAL INFECTION; BACTERIUM CULTURE; CHRONIC BRONCHITIS; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; FRONTAL SINUSITIS; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HEALTH CARE COST; HEART ARRHYTHMIA; HUMAN; IN VITRO STUDY; INTESTINE FLORA; LIVER DYSFUNCTION; MYCOSIS; NAUSEA; NECROSIS; NOSE SECRETION; PHARMACOGENETICS; PHARYNGITIS; PRACTICE GUIDELINE; RHINOSINUSITIS; SEIZURE; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; TONSILLITIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VAGINITIS; VOMITING;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 33846002008     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.6.923     Document Type: Article

References (43)

1. Sande MA, Gwaltney JM. Acute community-acquired bacterial sinusitis; continuing challenges and current management. Clin. Infect. Dis. 39, S151-S158 (2004).
2. Gwaltney JM Jr. Acute community-acquired sinusitis. Clin. Infect. Dis. 23, 1209-1225 (1996).
3. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol. Head Neck Surg. 130(Suppl. 1), 1-45 (2004).
4. Ray NF, Baraniuk JN, Thamer M et al. Healthcare expenditure for sinusitis in 1996: contribution of asthma, rhinitis and other airways disorders. J. Allergy Clin. Immunol. 103(3 Pt 1), 401-407 (1999).
5. Goetzel RZ, Hawkins K, Ozmikowski RJ, Wang S. The health and productivity cost burden of the 'Top 10' physical and mental health conditions affecting 6 large US employers in 1999. J. Occup. Environ. Med. 45(1), 5-14 (2003).
6. Coughlin CM, Nelson M, Merchant S, Gondek K. Costs of broad-spectrum antibiotic use for acute sinusitis, chronic bronchitis, and pneumonia in a managed care population. Manag. Care Interface 16(6), 34-40 (2003).
7. Felmingham D, White AR, Jacobs MR et al. The Alexander Project: the benefits from a decade of surveillance. J. Antimicrob. Chemother. 56(Suppl. S2), ii3-ii21 (2005).
8. Hoban D, Waites K, Felmingham D. Antimicrobial susceptibility of community-aquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study. Diagn. Microbiol. Infect. Dis. 45(4), 251-259 (2003).
9. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-1. J. Infect. 48(1), 56-65 (2004).
10. Doern GV, Richter SS, Miller A et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance in certain antimicrobial classes? Clin. Infect. Dis. 41, 139-148 (2005).
11. Thornsberry C, Sahm DF, Kelly LJ et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results form the TRUST Surveillance Program, 1999-2000. Clin. Infect. Dis. 34(Suppl. 1), S1-S16 (2002).
12. Zhanel GG, Palatnick L, Nichol KSA et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47(6), 1867-1874 (2003).
13. Jones ME, Tillotson GS, Flamm RK et al. Multidrug-resistant Streptococcus pneumoniae (MDR-SP) in US metropolitan areas 2003/4. Implications for antimicrobial therapy? (FAST study, 2004). Poster A-073. 105th American Society for Microbiology General Meeting. June 5-9, Atlanta, GA, USA (2005).
14. Canton R, Morosini M, Enright MC, Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae. data from the global PROTEKT surveillance programme. J. Antimicrob. Chemother. 52, 944-952 (2003).
15. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin. Infect. Dis. 41, 118-121 (2005).
16. Bhavnani SM, Hammel JP, Jones RN, Ambrose PG. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn. Microbiol. Infect. Dis. 51, 31-37 (2005).
17. Karlowsky JA, Hoban DJ, DeCorby MR et al. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance Study. Antimicrob. Agents Chemother. 50, 2251-2254 (2006).
18. Heilmann KP, Rice CL, Miller AL et al. Decreasing prevalence of β-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States. Antimicrob. Agents Chemother. 49(6), 2561-2564 (2005).
19. Farrell DJ, Morrissey I, Bakker S et al. Global distribution of TEM-1 and ROB-1 β-lactamases in Haemophilus influenzae. J. Antimicrob. Chemother. 56, 773-776 (2005).
20. Fluit AC, Florjin A, Verhoef J, Milatovic D. Susceptibility of European β-lactamase-positive and -negative Haemophilus influenzae isolates from the periods 1997/1998 and 2002/2003. J. Antimicrob. Chemother. 56, 133-138 (2005).
21. Jansen WT, Verel A, Beitsma M et al. Longitudinal European surveillance study of antibiotic resistance of Haemophilus influenzae. J. Antimcrob. Chemother 58, 873-877 (2006).
22. Qin L, Watanabe H, Asoh N et al. Antimicrobial susceptibility and genetic characteristics of Haemophilus influenzae isolated from patients with respiratory tract infections between 1987-2000, including β-lactmase-negative ampicillin-resistant strains. Epidemiol. Infect. 6, 1-4 (2006).
23. Benninger MS, Payne S, Ferguson BJ, Hadley JA. Endoscopically directed middle meatal cultures versus maxillary sinus taps in acute maxillary rhinosinusitis: a meta-analysis. Otolaryngol. Head Neck Surg. 134, 3-9 (2006).
24. Klossek JM, Federspil P. Update on treatment guidelines for acute bacterial sinusitis. Int. J. Clin. Pract. 59, 230-238 (2005).
25. Agence Francais de Securite Sanitaire des Produits de Sante. Systemic antibiotic treatment in upper and lower respiratory tract infections: official French guidelines. CMI 9(12), 1162-1178 (2003).
26. Sociedad Espanola de Quimioterapia y Sociedad Espanola de Otorrinolaringologia y Patalogia Cervico-Facial. Diagnostico y tratamiento antimicrobiano de las sinusitis. Rev. Esp. Quimioterap. 16(2), 239-251 (2003).
27. Sokol W. Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 Respiratory Surveillance Program. Am. J. Med. 111(9A), 19S-24S (2001).
28. Taghizadeh F, Hadley JA, Osthuthorpe JD. Pharmacological treatments for rhinosinusitis. Exp. Opin. Pharmacother. 3, 305-313 (2002).
29. Dalhoff A, Janjic N, Echols R. Redefining penems. Biochem. Pharmacol. 71(7), 1085-1095 (2006).
30. Critchley IA, Karlowsky JA, Draghi DC et al. Activities of faropenem, an oral β-lactam, against recent US isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother. 46(2), 550-555 (2002).
31. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. In vitro activity of faropenem against 5460 clinical bacterial isolates from Europe. J. Antimicrob. Chemother. 50(2), 293-299 (2002).
32. Milazzo I, Blandino G, Caccamo F et al. Faropenem, a new oral penem: antibacterial activity against selected anaerobic and fastidious periodontal isolates. J. Antimicrob. Chemother. 51(3), 721-725 (2003).
33. Shimada J, Takemura H, Funashashi K, Kajiura T. Surveillance of susceptibility of clinical isolates to various antibiotics including faropenem: antibacterial activity against aerobic bacteria isolated from common infections during 1998-2003. Jap. J. Chemo. 51, 680-692 (2003).
34. Kaieda S, Yano H, Okitsu N et al. In-vitro investigation of the indirect pathogenicity of β-lactamase-producing microorganisms in the nasopharyngeal microflora. Int. J. Pediatr. Otorhinolaryngol. 69(4), 479-485 (2005).
35. Voith B, Wilding I, Wray A et al. Absorption of faropenem daloxate delivered locally to different sites of the gastrointestinal tract by an Enterion capsule (Abstract). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. December 16-19, IL, USA (2001).
36. Schuehly U, Voith B, Voigt U et al. Safety, tolerability, and pharmacokinetics following multiple oral doses of faropenem daloxate and impact on fecal and oral flora (plus poster) (494). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17-20, Toronto, Canada (2000).
37. Voith B, Schuehly U, Voigt U et al. Influence of food intake on the pharmacokinetics, safety and tolerability of a single dose of faropenem daloxate (plus poster) (ABRStract). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17-20, Toronto, Canada (2000).
38. Weinstein DM, Takahashi A. Faropenem demonstrates lower antigenic cross-reactivity compared to other β-lactam antibiotics in a rabbit immunogenicity model (plus poster) (499). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17-20, Toronto, Canada (2000).
39. Kowalsky S, Upchurch J, Rosemore M et al. Prospective, randomized, double-blind, three-armed, multicenter, comparative trial to evaluate the efficacy and safety of faropenem daloxate 300 mg PO, BID for 7 days versus faropenem daloxate 300 mg PO, BID for 10 days versus cefuroxime axetil 250 mg PO, BID for 10 days in the treatment of acute bacterial sinusitis. Study 100288 (Abstract). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. December 16-19, Washington, DC, USA (2005).
40. Siegert R, Berg O, Gehanno P et al. Comparison of the efficacy and safety of faropenem daloxate and cefuroxime axetil for the treatment of acute bacterial maxillary sinusitis in adults. Eur. Arch. Otorhinolaryngol. 260(4), 186-194 (2003).
41. Singh S, Echols R. Prospective, multicenter, nonblind, uncontrolled trial to evaluate the efficacy and safety of faropenem daloxate 300 mg PO, BID for 7 days in the treatment of acute bacterial sinusitis. Study 100287 (Abstract). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. December 16-19, Washington, DC, USA (2005).
42. Kowalsky S, Tosiello R, Echols R. Faropenem medoxomil (FM) In: The Treatment Of Acute Bacterial Sinusitis (ABRS): An Integrated Analysis. 16th European Congress of Clinical Microbiology and Infectious Diseases. Nice, France, Abstract P-1715 (2006).
43. Echols R, Tosiello R. An integrated safety analysis of faropenem medoxomil (FM): results of 5,023 subjects from Phase II/III clinical trials. 16th European Congress of Clinical Microbiology and Infectious Diseases. Nice, France, Abstract P-1716 (2006).